Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits
HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the recent launch of the Vericheck ddPCRTM Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit. The kits provide rapid, cost-effective solutions for the absolute quantification of replication competent lentivirus (RCL) and replication competent adeno-associated virus (RCAAV), supporting the safe and effective production of cell and gene therapies.
Replication competent viruses (RCVs) can infect cells and replicate to produce additional virions. RCVs can be generated through recombination events between the transfer plasmid and either the production plasmids or the packaging cell line's genome. Fundamental to the safety of emerging cell and gene therapies, RCV testing of samples must be performed throughout the production process.
Bio-Rad's Vericheck ddPCR kits for detection of RCL and RCAAV provide a validated solution for highly specific and highly sensitive detection and quantification of viral replication genes, potentially indicating an RCV. The tests are designed for Bio-Rad's QX Droplet Digital PCR (ddPCR) platforms, with a simple workflow including automated data analysis and flexible sample throughput. Compared to traditional cell culture–based methods for RCV testing, the kits significantly reduce cost and turnaround time, achieving results in as little as 8 hours.
"As the number of cell and gene therapies entering the market increases, we see a growing emphasis on the need for products to ensure safety and efficacy across production processes. We believe that Droplet Digital PCR solutions can help address this unmet need," said Carolyn Reifsnyder, Senior Director of Marketing at Bio-Rad. "The introduction of Bio-Rad’s newest Vericheck ddPCR kits for RCL and RCAAV to our growing portfolio reflects our ongoing commitment to providing innovative QC tools to support advances in the cell and gene therapy space."
To learn more about the Vericheck ddPCR kits for RCL and RCAAV detection, visit bio-rad.com/ddPCR-Vericheck-RCV.
BIO-RAD and Droplet Digital are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909
katrina_academia@bio-rad.com
Zyme Communications
Esmé Walters
+44 (0) 7737 543244
esme.walters@zymecommunications.com